NASDAQ:LNTH - Lantheus Stock Price, Forecast & News

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings results on Thursday, October, 31st. The medical equipment provider reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.07. The medical equipment provider had revenue of $85.80 million for the quarter, compared to analyst estimates of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. Lantheus's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the firm earned $0.24 earnings per share. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Lantheus.

Lantheus issued an update on its fourth quarter earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $0.27-$0.30 for the period, compared to the Thomson Reuters consensus estimate of $0.34. The company issued revenue guidance of $89-$91 million, compared to the consensus revenue estimate of $92.84 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Media headlines about LNTH stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lantheus earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Lantheus.

Lantheus saw a decline in short interest in November. As of November 15th, there was short interest totalling 1,210,000 shares, a decline of 9.7% from the October 31st total of 1,340,000 shares. Based on an average trading volume of 411,400 shares, the short-interest ratio is presently 2.9 days. Approximately 3.2% of the shares of the company are short sold. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO) and GeneNews (GNWSF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Energy Transfer LP Unit (ET), Gerdau (GGB), Cypress Semiconductor (CY), Akorn (AKRX), Ares Capital (ARCC), Endocyte (ECYT), Exelixis (EXEL) and Paratek Pharmaceuticals (PRTK).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.76%), Vaughan Nelson Investment Management L.P. (3.49%), Tamarack Advisers LP (1.91%), Voya Investment Management LLC (1.68%), Rice Hall James & Associates LLC (1.09%) and Peregrine Capital Management LLC (0.56%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vaughan Nelson Investment Management L.P., Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC, Cadence Capital Management LLC, Hancock Whitney Corp, State Street Corp and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

LNTH stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Rice Hall James & Associates LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, Tealwood Asset Management Inc., Hussman Strategic Advisors Inc., Chicago Equity Partners LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $20.51.

Lantheus has a market capitalization of $804.98 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]